• $427.5M
    Market Cap
  • -70.58%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 71
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders

Abbott Cooper PLLC is investigating potential fiduciary duty violations by the board of Indaptus Therapeutics in connection with a private placement of preferred stock. The investigation targets stockholders who held shares prior to December 22, 2025.

06/17/2026, 11:02 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$3.60
$4.04
$3.71
1-Year Range
$0.37
$12.87
$3.71
Latest Close$3.71
Change
-$0.06 (-1.75%)
Volume181,335
Market Cap$427.5M
Shares Outstanding113.2M
P/E (TTM)-0.32
Diluted EPS (TTM)-$11.90
Enterprise Value$426.0M

Information as of 06/23/2026

Company Profile

INDAPTUS THERAPEUTICS INC
https://indaptusrx.com
$427.5M
Market Cap
-$3.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
Three Columbus Circle, New York, NY, United States, 10019
646 427 2727

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Key Executives

  • Walt Addison Linscott
  • Michael J. Newman
  • Junyi Dai
  • Yu Ding

Current Ownership Distribution

  • Insiders93.9M (86.36%)
  • Institutions11.0M (10.16%)
  • Mutual Funds3.8M (3.48%)
  • Other0 (0.00%)